Connect with us

Hi, what are you looking for?


Bayer share price has nosedived: is it a good turnaround stock?


Bayer (ETR: BAYN) share price plunged to the lowest level since February 6 after the company lowered its forward guidance. It retreated to a low of €55.95, which was about 15% below the highest level this year. It remains relatively above the lowest level this year.

Bayer guidance cut

Bayer, the giant German company, published results that were significantly stronger than what analyst were expecting. In total, the company’s total revenue jumped to over €50.7 billion in 2022 from the previous €44 billion. This happened as demand for its products rose following Russia’s invasion of Ukraine.

Its EBITDA rose from over €6 billion to over €13 billion while its net income jumped to over €4 billion. This makes it one of the most profitable DAX index constituents. However, the Bayer stock price plunged after the company warned that its business would slow in 2023.

It expects that its core earnings per share will come in at €7.40 this year, slightly below the estimated €7.90. Further, the company expects that its crop science business will have an extremely slow growth this year as prices retreat.

Despite the crash, Bayer share price has numerous catalysts going forward. First, the company will soon have a new Chief Executive Officer (CEO) from Roche who will be tasked with turning around the company. He will replace a CEO who has helped destroy shareholder value substantially.

As we saw with Rolls-Royce, a new CEO can inspire change and boost its stock. Second, Bayer could split its business into two companies. One could focus on crop science and the other one pharma and human health. Some analysts believe that separating the two businesses has the ability to create shareholder value. Also, it will help it deal with the Monsanto lawsuits, which we covered about here.

Further, Bayer is one of the cheapest companies in the industry. It trades at ~20% discount from its global peers, which makes it a good value stock. With bond yields rising and demand for value and dividend paying company is expected to remain high for a while.

Bayer share price forecast

Bayer share price

The 4H chart shows that the Bayer stock price made a down-gap after the weak forward guidance. As it crashed, the stock moved to the lowest point since the first week of February. It has moved below the 25-period and 50-period moving averages and the key support at 56.39 euros, the highest point on November 29.

Therefore, I suspect that this gap will take more time to be filled. As such, the next key point to watch will be the psychological point at 50 euros. The stop-loss of this trade will be at 57,50 euros.

The post Bayer share price has nosedived: is it a good turnaround stock? appeared first on Invezz.

You May Also Like


Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...


Mimiq, Inc is announcing today the launch of their new product, Mimiq Track, at CES as part of their latest product line to operate...


On this week’s edition of Stock Talk with Joe Rabil, Joe looks at the longer-term picture for stocks like AAPL, TSLA, and more. He...

Latest News

Kevin McCarthy’s difficult road to becoming House speaker ended early Saturday morning after Republicans appeared to have miscounted the number of votes they needed...

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023